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A saving grace of the COVID-19 pandemic 
in high- income and upper middle- income 
countries has been the relative sparing 
of children. As the disease spreads across 
low- income and middle- income countries 
(LMICs), long- standing system vulnerabil-
ities may tragically manifest, and we worry 
that children will be increasingly impacted, 
both directly and indirectly. Drawing on our 
shared child pneumonia experience glob-
ally, we highlight these potential impacts on 
children in LMICs and propose actions for a 
collective response.
Current data suggest children are suscep-
tible to severe acute respiratory syndrome 
coronavirus 2 (SARS- CoV-2) infection but 
are less likely than adults to become severely 
ill.1–4 Although at first glance these data 
appear reassuring, the child pneumonia, 
and broader global child health, experi-
ence provides a forewarning of what may be 
coming in LMICs. High- income countries 
(HICs) have an under-5 pneumonia mortality 
rate of 3 per 100 000.5 In contrast, the rate 
in LMICs is 200 per 100 000 population, with 
pneumonia the leading infectious cause of 
under-5 death globally.5 While yet unknown, 
COVID-19, a viral pneumonia syndrome, may 
impact children in LMICs more severely than 
what has been observed to date.
The risk factors for poor outcomes in 
pneumonia are overwhelmingly more prev-
alent in LMICs than HICs. These include 
severe malnutrition, low immunisation 
uptake, nutritional anaemia, HIV expo-
sure or infection, air pollution, poverty, low 
parental education and, crucially, limited 
access to high- quality acute healthcare.6 7 In 
HICs, vulnerable children are being actively 
‘shielded’ from infection, but in LMICs, 
most will remain exposed.
The indirect effects of the COVID-19 
response need attention as they are an enor-
mous threat to the well- being of children. 
These include widespread parental unem-
ployment, disrupted education, food and 
housing insecurity and threats to vital preven-
tive health programmes, like immunisation, 
antenatal care, infant feeding and mental 
health. The acute care workforce may soon 
be overwhelmed by COVID-19 needs, and we 
anticipate critical healthcare services being 
diverted away from mothers and children. 
Delays in care seeking may worsen, resulting 
in more severe illness. So, while transmis-
sion of respiratory pathogens may be slowed 
by pandemic response measures, these 
measures could accentuate well- established 
risk factors for poor paediatric outcomes and 
undermine healthcare systems’ abilities to 
respond.
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What can be done to protect children in LMICs? 
First, we must prevent the collapse of vital acute care 
(oxygen, antibiotics, personal protective equipment 
(PPE)), preventive services (immunisation, maternity 
care, breastfeeding and nutrition programmes, HIV and 
malaria prevention) and supply chains and take oppor-
tunities for system strengthening that could be a legacy 
of the pandemic. Maintaining a critical workforce in 
maternal and child health, enabling healthcare workers 
to use PPE and empowering community health workers 
to engage with communities in the response are essential. 
These measures, taken locally with decisive international 
support, are likely to save more children’s lives than 
advanced intensive care and should benefit children with 
COVID-19 and other illnesses, including pneumonia.
Second, COVID-19 testing in LMICs needs massive 
upscaling and outreach. If we are to understand paedi-
atric COVID-19, surveillance systems—both pandemic 
and pneumonia focused—need investment for rapid 
scale- up and testing of children with respiratory illnesses 
for SARS- CoV-2, testing paediatric contacts of adult cases 
and accurately reporting child deaths.
Third, pandemic lockdown strategies should main-
tain vital access to care and be tailored to the partic-
ular social, economic and health environments of 
LMICs. This may not mean following the approach of 
HICs. Rather, LMICs should also build on their expe-
rience and expertise gained during other epidemics 
and make decisions based on their reality, workforce 
capacity, population density and migration patterns. 
Examples could be establishing separate areas in clinics 
for preventative care by dedicated non- respiratory 
staff, home vaccination visits, outposts responsible for 
delivery of household essentials to COVID-19 affected 
households, retraining newly unemployed people to 
assist with case finding and contact tracing and sewing 
groups to produce face masks to support widespread 
mask strategies.
Fourth, research is key to better understanding 
COVID-19 fundamentals on children, younger and 
older, including their role in transmission dynamics, 
spectrum of illness and outcomes, the impact of 
comorbidities and common coinfections (viral, bacte-
rial, mycobacterial and parasitic) and how broader 
pandemic responses impact on health behaviours 
and outcomes. To accomplish this requires COVID-19 
surveillance and rapid cycle research on the effects of 
pandemic response strategies and context- informed 
modelling using the best available data and locally 
relevant assumptions. Understanding COVID-19 in 
children is essential to developing informed, nuanced 
pandemic responses, including eventual vaccina-
tion strategies. These efforts must be country- driven, 
network- building, joint global initiatives supported by 
the international community for the benefit of all.
We expect children in LMICs may be seriously 
impacted by COVID-19, potentially both directly and 
indirectly. Balanced strategies that protect children 
must be central to coordinated and cooperative global 
pandemic response efforts.
Author affiliations
1Projahnmo Research Foundation, Dhaka, Bangladesh
2NIHR Global Health Unit on Respiratory Health (RESPIRE), London, United Kingdom
3University of North Carolina Project Malawi, Lilongwe, Malawi
4Department of Pediatrics, University of North Carolina- Chapel Hill, Chapel Hill, 
North Carolina, USA
5KEMRI- Wellcome Trust Research Programme, Nairobi, Kenya
6Malaria Consortium, London, United Kingdom
7Department of International Health, Johns Hopkins Bloomberg School of Public 
Health, Baltimore, Maryland, USA
8Center for Global Health, Usher Institute, University of Edinburgh Medical School, 
Edinburgh, United Kingdom
9Division of Pulmonary and Critical Care, Department of Medicine, Johns Hopkins 
University School of Medicine, Baltimore, Maryland, USA
10Dhaka Hospital, Nutrition and Clinical Services Division, International Centre for 
Diarrhoeal Disease and Research, Bangladesh (icddr,b), Dhaka, Bangladesh
11Global Health Institute, University College London, London, United Kingdom
12Centre for Inflammation Research, University of Edinburgh, Edinburgh, United 
Kingdom
13Paediatric Intensive Care Unit, Royal Children’s Hospital, Melbourne, Victoria, 
Australia
14Department of Paediatrics, University of Melbourne, Melbourne, Victoria, Australia
15School of Medicine and Health Sciences, University of Papua New Guinea, 
Goroka, Papua New Guinea
16Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, 
University of Oxford, Oxfordshire, United Kingdom
17Division of Paediatric Pulmonology, Department of Paediatrics, College of 
Medicine and University College Hospital, Ibadan, Nigeria
18Global and Tropical Health Division, Menzies School of Health Research, Charles 
Darwin University, Darwin, Northern Territory, Australia
19Clinical Trial Center, University of Washington, Seattle, United States
20Centre for International Child Health, MCRI, University of Melbourne, Melbourne, 
Victoria, Australia
21Department of Paediatrics, University College Hospital Ibadan, Ibadan, Nigeria
22Division Paediatric Pulmonology, Department of Paediatrics, University of Cape 
Town, Cape Town, South Africa
23Department of Community Medicine and School of Public Health, Postgraduate 
Institute of Medical Education and Research, Chandigarh, India
24Desmond Tutu TB Centre, Department of Paediatrics and Child Health, Faculty of 
Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa
25Department of Pediatrics, Section of Pediatric Emergency Medicine, Baylor 
College of Medicine, Houston, United States
26Pulmonology & Infectious Disease Unit, Department of Paediatrics & Child Health, 
University of Ilorin/University of Ilorin Teaching Hospital, Ilorin, Nigeria
27Department of Global Public Health, Karolinska Institutet, Stockholm, Sweden
28Gangarosa Department of Environmental Health, Rollins School of Public Health, 
Emory University, Atlanta, Georgia, United States
29Department of Global Health and Population, Harvard T.H. Chan School of Public 
Health, Boston, United States
30Instituto de Investigación Nutricional, Lima, Peru
31Department of Pediatrics, School of Medicine, Vanderbilt University, Nashville, 
Tennessee, United States
32Community Health Sciences Unit, Malawi Ministry of Health, Lilongwe, Malawi
33MRC Unit, The Gambia at LSHTM, Fajara, Gambia
34Faculty of Infectious & Tropical Diseases, LSHTM, London, United Kingdom
35Murdoch Children’s Research Institute, Melbourne, Victoria, Australia
36Center for Health Studies, Universidad del Valle de Guatemala, Guatemala City, 
Guatemala
37Divisions of Pulmonary Medicine and Global Health, Department of Pediatrics, 
Massachusetts General Hospital, Boston, Massachusetts, USA
38Department of Child Health, University of Benin Teaching Hospital, Benin City, 
Nigeria
39Papua New Guinea Institute of Medical Research, Goroka, Papua New Guinea
40Department of Infectious Diseases, Imperial College London, London, United 
Kingdom
41Baylor College of Medicine Children’s Foundation – Lesotho, Maseru, Lesotho
 o
n
 M
ay 28, 2020 by guest. Protected by copyright.
http://gh.bmj.com/
BM
J G
lob Health: first published as 10.1136/bmjgh-2020-002844 on 26 May 2020. Downloaded from 
Ahmed S, et al. BMJ Global Health 2020;5:e002844. doi:10.1136/bmjgh-2020-002844 3
BMJ Global Health
42Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA
43The International Pediatric AIDS Initiative (BIPAI) at Texas Children’s Hospital, 
Baylor College of Medicine, Houston, Texas, USA
44Department of Paediatrics and Child Health, Stellenbosch University, Cape Town, 
South Africa
45Division of Paediatric Pulmonology, Department of Paediatrics, Chris Hani 
Baragwanath Academic Hospital, Faculty of Health Sciences, University of the 
Witwatersrand, Johannesburg, South Africa
46Respiratory and Meningeal Pathogens Research Unit, Medical Research Council, 
University of the Witwatersrand, Johannesburg, South Africa
47Department of Pediatric Infectious Diseases, Institute of Tropical Medicine, 
Nagasaki University, Nagasaki, Japan
48Department of Paediatrics and Child Health, Red Cross War Memorial Children’s 
Hospital, University of Cape Town, Cape Town, South Africa
49SA- MRC Unit on Child and Adolescent Health, University of Cape Town, Cape 
Town, South Africa
50Department of Paediatrics: Child & Youth Health, University of Auckland, Auckland, 
New Zealand
51Johns Hopkins Global Program in Pediatric Respiratory Sciences, Eudowood 
Division of Pediatric Respiratory Sciences, Department of Pediatrics, Johns Hopkins 
School of Medicine, Baltimore, Maryland, USA
Twitter Mike English @ProfMikeEnglish, Nicholas SS Fancourt @fantwit, Hamish 
R Graham @grahamhamish, Shubhada Hooli @ShubhadaH and Eric D McCollum 
@tinylungsglobal
Contributors EDM, SA and TM wrote the first draft of the comment. EDM, SA, 
TM, SRCH, NBZ, HRG, CK and ME provided critical review and editing of comment. 
All authors reviewed subsequent drafts and agreed on the final version of this 
comment.
Funding The authors have not declared a specific grant for this research from any 
funding agency in the public, commercial or not- for- profit sectors.
Competing interests None declared.
Patient and public involvement Patients and/or the public were involved in the 
design, or conduct, or reporting, or dissemination plans of this research. Refer to 
the Methods section for further details.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; internally peer reviewed.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY- NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non- commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the 
use is non- commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
ORCID iDs
Salahuddin Ahmed http:// orcid. org/ 0000- 0001- 6771- 0638
Tim Colbourn http:// orcid. org/ 0000- 0002- 6917- 6552
Mike English http:// orcid. org/ 0000- 0002- 7427- 0826
Nicholas SS Fancourt http:// orcid. org/ 0000- 0002- 1772- 9960
Hamish R Graham http:// orcid. org/ 0000- 0003- 2461- 0463
Shubhada Hooli http:// orcid. org/ 0000- 0003- 4596- 448X
Peter P Moschovis http:// orcid. org/ 0000- 0002- 9664- 5959
Brian Wahl http:// orcid. org/ 0000- 0002- 0037- 7364
Eric D McCollum http:// orcid. org/ 0000- 0002- 1872- 5566
REfEREncEs
 1 Dong Y, Mo X, Hu Y, et al. Epidemiology of COVID-19 among children 
in China. Pediatrics 2020:e20200702.
 2 Lu X, Zhang L, Du H, et al. SARS- CoV-2 infection in children. N Engl J 
Med 2020;382:1663–5.
 3 CDC COVID-19 Response Team. Coronavirus Disease 2019 in 
Children - United States, February 12- April 2, 2020. MMWR Morb 
Mortal Wkly Rep 2020;69:422–6.
 4 Tagarro A, Epalza C, Santos M, et al. Screening and severity of 
coronavirus disease 2019 (COVID-19) in children in Madrid, Spain. 
JAMA Pediatr 2020. doi:10.1001/jamapediatrics.2020.1346. [Epub 
ahead of print: 08 Apr 2020].
 5 GBD 2017 Lower Respiratory Infections Collaborators. Quantifying 
risks and interventions that have affected the burden of lower 
respiratory infections among children younger than 5 years: an 
analysis for the global burden of disease study 2017. Lancet Infect 
Dis 2020;20:60–79.
 6 Sonego M, Pellegrin MC, Becker G, et al. Risk factors for mortality 
from acute lower respiratory infections (ALRI) in children under five 
years of age in low and middle- income countries: a systematic 
review and meta- analysis of observational studies. PLoS One 
2015;10:e0116380.
 7 Lazzerini M, Sonego M, Pellegrin MC. Hypoxaemia as a mortality 
risk factor in acute lower respiratory infections in children in low and 
middle- income countries: systematic review and meta- analysis. PLoS 
One 2015;10:e0136166.
 o
n
 M
ay 28, 2020 by guest. Protected by copyright.
http://gh.bmj.com/
BM
J G
lob Health: first published as 10.1136/bmjgh-2020-002844 on 26 May 2020. Downloaded from 
